STOCK TITAN
  1. Home
  2. Sec-filings
  3. ser
  4. [8-K] Serina Therapeutics, Inc. Reports Material Event

Executive pay changes and new CTO at Serina Therapeutics (NYSE: SER)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported leadership and governance updates. Its subsidiary, Serina Therapeutics (AL), Inc., promoted Srini Tenjarla, Ph.D., to Chief Technology Officer, increasing his annual base salary to $425,000, effective back to March 15, 2026. The Company also raised Chief Executive Officer Steve Ledger’s annual base salary to $500,000, effective as of September 9, 2024, and paid the retroactive amount in a lump sum in April 2026.

The Board approved amended and restated bylaws effective April 15, 2026. The bylaws add detailed provisions for appointing Co-Chairs of the Board, allowing a Chair or any Co-Chair to call special stockholder meetings and preside over Board and stockholder meetings, with each Co-Chair holding the same authority and powers, subject to coordination expectations.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
CTO base salary $425,000 per year Annual base salary for Srini Tenjarla effective March 15, 2026
CEO base salary $500,000 per year Annual base salary for CEO Steve Ledger effective September 9, 2024
Bylaws adoption date April 15, 2026 Amended and restated bylaws approved and adopted by the Board
CTO promotion date April 20, 2026 Date Serina (AL) named Srini Tenjarla as Chief Technology Officer
Retroactive CEO pay timing April 2026 lump sum Retroactive portion of CEO base salary increase paid
amended and restated bylaws regulatory
"the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
Co-Chairs of the Board of Directors regulatory
"The Bylaws include provisions relating to the appointment of Co-Chairs of the Board of Directors"
special meetings of stockholders regulatory
"clarifying that special meetings of stockholders may be called by the Chair or any Co-Chair"
Special meetings of stockholders are gatherings called outside the regular annual meeting to vote on specific, often urgent matters such as mergers, major asset sales, or changes in board control. For investors these meetings matter because they can produce quick, binding decisions that affect a shareholder’s ownership value or control rights—think of it like an emergency family meeting to decide whether to sell the house, where the outcome directly changes everyone’s stake.
Emerging growth company regulatory
"Emerging growth company o o Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Understanding 8-K Material Events →
0001708599false12/3100017085992026-04-152026-04-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 15, 2026
Serina Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware1-3851982-1436829
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
601 Genome Way, Suite 2001
Huntsville, Alabama 35806
(Address of principal executive offices)
(256) 327-9630
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock, par value $0.0001 per shareSERNYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Chief Technology Officer

On April 20, 2026, Serina Therapeutics (AL), Inc. (the “Serina (AL)”), a wholly owned subsidiary of Serina Therapeutics, Inc. (the “Company”), named Srini Tenjarla, Ph.D., its Chief Technology Officer. Dr. Tenjarla had previously served as Serina (AL)’s Senior Vice President of CMC and Formulation since July 2024. In connection with the promotion, Dr. Tenjarla’s annual base salary was increased to $425,000, effective back to March 15, 2026.

Chief Executive Officer Compensation

On April 15, 2026, the Company increased the annual base salary of Steve Ledger, the Company’s Chief Executive Officer, to $500,000. The increase in base salary was pursuant to Mr. Ledger’s employment agreement upon the satisfaction of certain strategic goals, and is effective as of September 9, 2024, the date of Mr. Ledger’s employment agreement. The Company has paid the retroactive portion of the base salary increase in a lump sum in April 2026.

Item 5.03     Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On April 15, 2026, the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company (the “Bylaws”), effective immediately.

The Bylaws include provisions relating to the appointment of Co-Chairs of the Board of Directors, including provisions clarifying that special meetings of stockholders may be called by the Chair or any Co-Chair, that the Chair or any Co-Chair may preside at meetings of stockholders and meetings of the Board of Directors, and that each Co-Chair has the same authority and powers as the Chair of the Board and may act independently of any other Co-Chair, subject to coordination expectations set forth in the Bylaws.

The Bylaws also include conforming updates and corrections.

The foregoing description of the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws, which are filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits
Exhibit
Number		Description
3.1
Amended and Restated Bylaws of Serina Therapeutics, Inc., adopted April 15, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERINA THERAPEUTICS, INC.
Date: April 15, 2026By:/s/ Steve Ledger
Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What executive leadership change did Serina Therapeutics (SER) announce?

Serina Therapeutics’ subsidiary promoted Srini Tenjarla, Ph.D., to Chief Technology Officer. He previously served as Senior Vice President of CMC and Formulation since July 2024, reflecting an internal advancement in technical leadership at the company’s Serina Therapeutics (AL), Inc. unit.

How did Serina Therapeutics (SER) change CTO compensation?

In connection with his promotion to Chief Technology Officer, Srini Tenjarla’s annual base salary was set at $425,000. The new salary is effective retroactively to March 15, 2026, increasing his compensation from his prior role as Senior Vice President of CMC and Formulation.

What is the new base salary for Serina Therapeutics (SER) CEO?

Serina Therapeutics increased Chief Executive Officer Steve Ledger’s annual base salary to $500,000. The raise became effective as of September 9, 2024, under his employment agreement after certain strategic goals were satisfied, with the retroactive portion paid in a lump sum in April 2026.

Why did Serina Therapeutics (SER) increase its CEO’s salary retroactively?

The CEO’s salary increase was triggered under Steve Ledger’s employment agreement upon satisfying certain strategic goals. As a result, his $500,000 annual base salary is effective from September 9, 2024, and the company paid the retroactive difference in a lump-sum payment during April 2026.

What changes did Serina Therapeutics (SER) make to its bylaws?

The Board adopted amended and restated bylaws on April 15, 2026, adding provisions for appointing Co-Chairs of the Board. The updates clarify that a Chair or any Co-Chair may call special stockholder meetings, preside at meetings, and hold equal authority and powers with coordination expectations.

How do the new Co-Chair provisions affect Serina Therapeutics (SER) governance?

Under the amended bylaws, each Co-Chair has the same authority and powers as the Chair of the Board. A Chair or any Co-Chair may independently call special stockholder meetings and preside over Board or stockholder meetings, subject to coordination expectations detailed in the bylaws.

Filing Exhibits & Attachments

4 documents

Other Documents